p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
about
NADPH oxidase in stroke and cerebrovascular diseaseEvolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target EngagementBiochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular systemChronic granulomatous diseaseProtein Oxidation in Aging: Does It Play a Role in Aging Progression?Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of AtherosclerosisNADPH oxidases: key modulators in aging and age-related cardiovascular diseases?3-nitrotyrosine modified proteins in atherosclerosisOut, damned dot: studies of the NADPH oxidase in atherosclerosisReactive oxygen species in inflammation and tissue injuryThe SecA2 secretion factor of Mycobacterium tuberculosis promotes growth in macrophages and inhibits the host immune responseHDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 productionAirway smooth muscle relaxation is impaired in mice lacking the p47phox subunit of NAD(P)H oxidaseNrf2 and the promotion of atherosclerosis: lessons to be learnedp47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseasesNuclear Factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in Atherosclerosis and Ischemia/Reperfusion Injury in the Heart.Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice.A copy number variation in human NCF1 and its pseudogenesOxidative risk for atherothrombotic cardiovascular disease.NADPH oxidases in vascular pathology.Nox2 mediates high fat high sucrose diet-induced nitric oxide dysfunction and inflammation in aortic smooth muscle cellsOxidative stress in the pathology and treatment of systemic lupus erythematosusNox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaquesNox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteriesRole of vascular oxidative stress in obesity and metabolic syndrome.Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo.Crossroads between peripheral atherosclerosis, western-type diet and skeletal muscle pathophysiology: emphasis on apolipoprotein E deficiency and peripheral arterial disease.The presence of p47phox in liver parenchymal cells is a key mediator in the pathogenesis of alcoholic liver steatosisNADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis.Deletion of metallothionein exacerbates intermittent hypoxia-induced oxidative and inflammatory injury in aorta.Antagonistic effect of TNF-alpha and insulin on uncoupling protein 2 (UCP-2) expression and vascular damage.Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase.Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association?NADPH oxidase links endoplasmic reticulum stress, oxidative stress, and PKR activation to induce apoptosisAssessment of atherosclerosis in chronic granulomatous diseaseThe nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in miceAgonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice.Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling.Role for Nox1 NADPH oxidase in atherosclerosis
P2860
Q26859140-65647231-1360-4357-91BF-059C74E72E19Q26861119-62A55624-5D11-492C-8A44-73A1B1401229Q26991619-44C33395-3868-4D0F-A59C-27F0341C8D2FQ27009322-2D70B4FC-38BB-4815-BB68-807642E15CD4Q27021668-3B1E649E-076A-4563-A008-5458A88BC3C2Q27315993-CDC4B065-B2A3-423F-8047-FF2B94D238D9Q28072348-1C305B25-4784-4077-A5B3-53E492647B02Q28083260-A75AEBFA-1CF1-40E0-AD9C-0EA7496A5C8FQ28364447-D86BE140-C7B1-47AD-8DDF-C5BA372A57EAQ28396273-4E3F6F6A-87C2-4701-B75B-2B8130701DF6Q28487596-F5622B31-137F-4D85-B4EC-D3BD0C1F2046Q28580308-44170A85-5E4E-48AE-BB6C-CAD3AFAEC1D5Q28588703-42A7E6C9-5E7E-49D2-8AF8-4A916BA12E0CQ29541148-E398B6D1-A43C-4AA9-975A-5D81FBAD849EQ30157297-FBDB6CAE-19F7-40A0-BE45-C0ACB20B8828Q30275291-F938CED0-D7E5-4D16-99FD-1714B77C4BFFQ33386022-267C8EAA-1F44-41BF-9201-8EFD96C4431EQ33533669-EC10A645-8748-46B0-B5A4-C6AB55EB983DQ33554184-D84ED887-E456-4845-AE8C-2186DA27B58DQ33632089-093B067B-9508-4F53-A542-89BA546EF961Q33680596-F5ED0CD2-A1EC-4ED8-BD63-830208E66A20Q33715508-5C7CA138-BDD3-4569-A25C-4DACE2B1CFDCQ33737346-9379D72B-BF1C-4931-BEFB-D6923E3CD3B2Q33744942-2532BEAE-EFED-4737-A4A7-EAEE0D16C31CQ33789308-D96DC48F-B1DF-44A2-A192-BB3B76585A74Q33869754-66D74886-62AC-4698-BC7A-BEC47A192EF5Q33885504-0FB8D0EF-EFFC-4DE8-8985-BD01046E76F4Q33997351-C47055D5-BE66-4B72-935F-A728BFD3F1C2Q34074465-8EB4FA05-3ACC-4C42-B3B3-DC550255BD10Q34074823-C89422CE-7BD0-4FB3-80A5-CAF865FBC7B3Q34079885-7AFD2E30-5519-476F-AE2A-1DC67851CB54Q34109196-18D62BF7-506E-4FC6-9BDD-50D17171A9DCQ34217495-0CCF0B9A-A176-4078-B87C-16684A7565C0Q34239967-B358FA39-6D6B-4B5E-9454-EA5FE62F1067Q34406716-6C4935E1-6402-4658-B6B1-833C77C0EC38Q34650014-65534683-B84A-428A-BCC3-DA933075A7F1Q34860956-6C82973D-00DB-4CB0-8DBD-9AC4C53BBB05Q34978758-4CC5C7A4-2B94-4212-B719-2A867D584AE3Q34979530-882B2D57-4967-41F9-ABD8-384C47A7854BQ35032392-81147FE9-CDDE-4D63-9653-DD606D566BAD
P2860
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@ast
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@en
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@nl
type
label
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@ast
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@en
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@nl
prefLabel
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@ast
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@en
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@nl
P2093
P2860
P3181
P1476
p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice
@en
P2093
C Patterson
M van der Merwe
P A Barry-Lane
S M Holland
P2860
P304
P3181
P356
10.1172/JCI11927
10.1172/JCI200111927
P407
P577
2001-11-01T00:00:00Z